Shares of over-the-counter drugmaker Perrigo sank early Friday after its stock owners rejected a hostile, $26 billion takeover bid from Mylan.» Read More
CNBC's David Faber reports Perrigo will reject Mylan's latest offer.
Mylan on Wednesday sweetened its bid for Perrigo.
CNBC's David Faber reports Mylan is increasing its bid for Mylan.
The "Halftime Report" traders give their trades for the second half.
Perrigo is set to close a huge deal for Omega Pharmaceuticals. Perrigo CEO Joseph Papa, discusses the benefits of the deal, and the company's move to Ireland.
Some of the names on the move ahead of the open.
We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.
The stock market might be making new all-time highs on almost a daily basis, but that doesn’t mean there isn’t bargain to be had.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts.